United States of America ex rel. Steven M. Camburn et al. v. Novartis Pharmaceuticals Corporation

  1. March 31, 2026

    Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks

    Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.

  2. March 31, 2026

    Compound GLP-1s, Anesthesia Prices And More In Court

    Law360 Healthcare Authority looks at appellate arguments from compounding pharmacies alleging they were wrongly barred from making their own versions of weight loss drugs, the Federal Trade Commission's suit over an alleged “rollup” of Texas anesthesiology practices, and other significant litigation developments this week.

  3. October 18, 2023

    Novartis Airs Mea Culpa As 2nd Circ. Probes Kickback Theory

    After a series of startling kickback cases, Novartis Pharmaceuticals on Wednesday contrasted its past misdeeds with newer accusations it bribed prescribers, and Second Circuit judges seemed sympathetic as they pressured a whistleblower's lawyer to substantiate a supposed nationwide scheme.

  4. September 14, 2022

    Multiple Sclerosis Drug Kickback Case Against Novartis Axed

    A New York federal judge has tossed a lawsuit accusing Novartis of running a scheme to improperly get doctors to prescribe a multibillion-dollar multiple sclerosis treatment, finding the former employee who brought the suit fell short on proving there was a kickback strategy.